Optimal oral antithrombotic regimes for patients with acute coronary syndrome: A network meta-analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Ye, Yicong ^a   Xie, Hongzhi ^a   Zeng, Yong ^a   Zhao, Xiliang ^a   Tian, Zhuang ^a   Zhang, Shuyang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; PRASUGREL; RIVAROXABAN; TICAGRELOR; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; CONFIDENCE INTERVAL; HEMORRHAGE; MYOCARDIAL INFARCTION; ODDS RATIO; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTITHROMBINS; CONFIDENCE INTERVALS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897498297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090986     Document Type: Article

References (33)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502. (Pubitemid 32758501)
2. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, et al. (2010) New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 56: 1542-1551.
3. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, et al. (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34: 1670-1680.
4. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33: 2569-2619.
5. Higgins JPT, Altman DG, Sterne JAC (2011). Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Oxford: The Cochrane Collaboration. pp8.1-8.22.
6. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
8. Robert CP, Casella G (2004) Monte Carlo Statistical Methods, 2nd ed. New York: Springer-Verlag.
9. Dias S, Sutton AJ, Ades AE, Welton NJ (2013) Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 33:607-617.
10. Brooks SP GA (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7: 434-455.
11. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
12. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015. (Pubitemid 350106708)
13. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, et al. (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367: 1297-1309.
14. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
15. Alexander JH, Lopes RD, James S, Kilaru R, He Y, et al. (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365: 699-708.
16. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, et al. (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366: 9-19.
17. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, et al. (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50: 1844-1851. (Pubitemid 350007959)
18. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, et al. (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119: 2877-2885.
19. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, et al. (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374: 29-38.
20. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, et al. (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111: 3366-3373. (Pubitemid 40931949)
21. Alexopoulos D, Xanthopoulou I, Mavronasiou E, Stavrou K, Siapika A, et al. (2013) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care 36: 2211-2216.
22. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, et al. (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60: 193-199.
23. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, et al. (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5: 797-804.
24. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, et al. (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61: 1601-1606.
25. Taylor AA, Shoheiber O (2003) Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 9: 324-332.
26. Dickson M, Plauschinat CA (2008) Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 8: 45-50. (Pubitemid 351311519)
27. Verheugt FW (2013) Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd? Eur Heart J 34: 1618-1620.
28. Komocsi A, Vorobcsuk A, Kehl D, Aradi D (2012) Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172: 1537-1545.
29. Ferreiro JL, Sibbing D, Angiolillo DJ (2010) Platelet function testing and risk of bleeding complications. Thromb Haemost 103: 1128-1135.
30. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al. (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216. (Pubitemid 44791162)
31. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, et al(2006)Compar-)Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476.
32. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al. (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863. (Pubitemid 37430344)
33. Subherwal S, Ohman EM, Mahaffey KW, Rao SV, Alexander JH, et al.(2013) Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. Am Heart J 165:644-654, 654.e1.